^
Association details:
| Biomarker: | CD70 overexpression |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Drug: | SGN-CD70A (DNA replication inhibitor, CD70-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models
Published date:
12/06/2021
Excerpt:
...CD70 is highly expressed in T cell lymphomas, especially in CTCL. SGN-CD70A inhibited cell growth and induced apoptosis in CD70-expressing CTCL cell-lines and primary tumors cells. Additionally, SGN-CD70A at 100 µg/kg and 300 µg/kg prolonged survival of PDXs in a dose-dependent manner.
DOI:
https://doi.org/10.1182/bloodadvances.2021005714
Source:
Title:
1844 - A CD70 antibody-drug conjugate is highly active and induces long term remission in patient-derived xenograft mouse models of cutaneous T cell lymphoma
Published date:
03/10/2021
Excerpt:
SGNCD70A inhibited cell growth and induced apoptosis of CD70+ CTCL cell lines and primary tumors from patient-derived xenograft (PDX) mice but had no inhibitory effect on CD70- lymphoblastic TCL cells and normal T cells....SGN-CD70A prolonged survival of treated mice in a dose-dependent fashion compared to untreated mice. Median survival was 21 days, 27.5 days (P=0.041), and 57 days (p<0.01) for the PBS control, SGN70A100 and SGN70A300 group, respectively....Our results showed that CD70 is highly expressed in mature TCL, especially in CTCL. Using CTCL PDX models, SGN-CD70A has marked anti-tumor activity, leading to long-term survival of treated mice.
